TELA Bio (TELA) Stock Price

TELA Bio Price

NASDAQ·CLOSED
0.91USD+0.07 (+8.02 %)
Market closed

Revenue has compounded at 44.4% per year over the past 8 years to 80.28 M USD. TELA Bio's net margin stands at -48.4%, up from -112.9% several years earlier. Analysts set a median price target of 4.08 USD, implying 348.8% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 62% above its 52-week low.

TELA Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of TELA Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how TELA Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing TELA Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

TELA Bio Stock Price History
DateTELA Bio Price
8/5/20260.91 USD
8/4/20260.84 USD
8/3/20260.74 USD
7/31/20260.73 USD
7/30/20260.71 USD
7/29/20260.67 USD
7/27/20260.61 USD
7/23/20260.71 USD
7/22/20260.73 USD
7/21/20260.72 USD
7/20/20260.72 USD
7/17/20260.73 USD
7/16/20260.75 USD
7/15/20260.79 USD
7/14/20260.75 USD
7/13/20260.88 USD
7/10/20260.85 USD
7/9/20260.86 USD
7/8/20260.86 USD
7/7/20260.89 USD
7/6/20260.74 USD
7/2/20260.72 USD
7/1/20260.72 USD
6/30/20260.75 USD
6/29/20260.73 USD
6/26/20260.71 USD
6/25/20260.74 USD
6/24/20260.75 USD
6/23/20260.79 USD
6/22/20260.85 USD
6/18/20260.80 USD
6/17/20260.86 USD
6/16/20260.90 USD
6/15/20260.80 USD
6/12/20260.86 USD
6/11/20260.91 USD
6/10/20260.94 USD
6/9/20260.94 USD
6/8/20260.85 USD
6/5/20260.88 USD
6/4/20260.88 USD
6/3/20260.86 USD
6/2/20260.91 USD
6/1/20260.90 USD
5/29/20260.97 USD
5/28/20260.90 USD
5/27/20260.87 USD
5/26/20260.81 USD
5/22/20260.89 USD
5/21/20260.92 USD
5/20/20260.95 USD
5/19/20260.86 USD
5/18/20260.83 USD
5/15/20260.90 USD
5/14/20260.99 USD
5/13/20260.96 USD
5/12/20261.02 USD
5/11/20260.97 USD
5/8/20261.02 USD
5/7/20261.10 USD
5/6/20260.99 USD
5/5/20261.13 USD
5/4/20261.09 USD
5/1/20260.99 USD
4/30/20260.88 USD
4/29/20260.86 USD
4/28/20260.78 USD
4/27/20260.80 USD
4/24/20260.67 USD
4/23/20260.62 USD
4/22/20260.62 USD
4/21/20260.62 USD
4/20/20260.63 USD
4/17/20260.68 USD
4/16/20260.73 USD
4/15/20260.66 USD
4/14/20260.60 USD
4/13/20260.56 USD
4/10/20260.57 USD
4/9/20260.60 USD
4/8/20260.64 USD
4/7/20260.69 USD
4/6/20260.63 USD
4/2/20260.60 USD
4/1/20260.57 USD
3/31/20260.62 USD
3/30/20260.56 USD
3/27/20260.67 USD
3/26/20260.75 USD
3/25/20260.69 USD
3/24/20260.76 USD
3/23/20260.83 USD
3/20/20260.78 USD
3/19/20260.75 USD
3/18/20260.72 USD
3/17/20260.80 USD
3/16/20260.74 USD
3/13/20260.74 USD
3/12/20260.77 USD
3/11/20260.78 USD
3/10/20260.84 USD
3/9/20260.89 USD
3/6/20260.90 USD
3/5/20260.85 USD
3/4/20260.84 USD
3/3/20260.83 USD
3/2/20260.86 USD
2/27/20260.87 USD
2/26/20260.82 USD
2/25/20260.85 USD
2/24/20260.79 USD
2/23/20260.77 USD
2/20/20260.72 USD
2/19/20260.80 USD
2/18/20260.78 USD
2/17/20260.77 USD
2/13/20260.79 USD
2/12/20260.79 USD
2/11/20260.82 USD
2/10/20260.82 USD
2/9/20260.81 USD
2/6/20260.81 USD
2/5/20260.80 USD
2/4/20260.84 USD
2/3/20260.87 USD
2/2/20260.95 USD
1/30/20261.00 USD
1/29/20260.97 USD
1/28/20260.96 USD
1/27/20260.98 USD
1/26/20260.97 USD
1/23/20260.98 USD
1/22/20260.96 USD
1/21/20260.98 USD
1/20/20260.93 USD
1/16/20261.02 USD
1/15/20260.99 USD
1/14/20261.01 USD
1/13/20261.07 USD
1/12/20261.06 USD
1/9/20261.09 USD
1/8/20261.09 USD
1/7/20261.12 USD
1/6/20261.14 USD
1/5/20261.10 USD
1/2/20261.14 USD
12/31/20251.18 USD
12/30/20251.12 USD
12/29/20251.10 USD
12/26/20251.14 USD
12/24/20251.14 USD
12/23/20251.14 USD
12/22/20251.14 USD
12/19/20251.13 USD
12/18/20251.14 USD
12/17/20251.15 USD
12/16/20251.18 USD
12/15/20251.13 USD
12/12/20251.15 USD
12/11/20251.13 USD
12/10/20251.17 USD
12/9/20251.17 USD
12/8/20251.13 USD
12/5/20251.15 USD
12/4/20251.14 USD
12/3/20251.15 USD
12/2/20251.14 USD
12/1/20251.13 USD
11/28/20251.15 USD
11/26/20251.12 USD
11/25/20251.14 USD
11/24/20251.14 USD
11/21/20251.17 USD
11/20/20251.06 USD
11/19/20251.08 USD
11/18/20251.18 USD
11/17/20251.14 USD
11/14/20251.00 USD
11/13/20251.11 USD
11/12/20251.14 USD
11/11/20251.19 USD
11/10/20251.19 USD
11/7/20251.17 USD
11/6/20251.18 USD
11/5/20251.20 USD
11/4/20251.29 USD
11/3/20251.37 USD
10/31/20251.23 USD
10/30/20251.30 USD
10/29/20251.32 USD
10/28/20251.44 USD
10/27/20251.48 USD
10/24/20251.48 USD
10/23/20251.49 USD
10/22/20251.48 USD
10/21/20251.51 USD
10/20/20251.48 USD
10/17/20251.53 USD
10/16/20251.50 USD
10/15/20251.48 USD
10/14/20251.49 USD
10/13/20251.50 USD
10/10/20251.46 USD
10/9/20251.48 USD
10/8/20251.53 USD
10/7/20251.57 USD
10/6/20251.52 USD
10/3/20251.56 USD
10/2/20251.51 USD
10/1/20251.50 USD
9/30/20251.49 USD
9/29/20251.50 USD
9/26/20251.45 USD
9/25/20251.48 USD
9/24/20251.55 USD
9/23/20251.54 USD
9/22/20251.61 USD
9/19/20251.62 USD
9/18/20251.59 USD
9/17/20251.51 USD
9/16/20251.58 USD
9/15/20251.58 USD
9/12/20251.58 USD
9/11/20251.62 USD
9/10/20251.57 USD
9/9/20251.60 USD
9/8/20251.62 USD
9/5/20251.59 USD
9/4/20251.59 USD
9/3/20251.65 USD
9/2/20251.74 USD
8/29/20251.78 USD
8/28/20251.80 USD
8/27/20251.76 USD
8/26/20251.80 USD
8/25/20251.83 USD
8/22/20251.77 USD
8/21/20251.72 USD
8/20/20251.69 USD
8/19/20251.74 USD
8/18/20251.70 USD
8/15/20251.58 USD
8/14/20251.60 USD
8/13/20251.47 USD
8/12/20251.60 USD
8/11/20251.86 USD
8/8/20251.72 USD
8/7/20251.67 USD
Access this data via the Eulerpool API
Get Free API Key

TELA Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
29.46 M USD
-29.68 M USD
-33.28 M USD
Jan 1, 2022
41.42 M USD
-40.25 M USD
-44.30 M USD
Jan 1, 2023
58.45 M USD
-41.61 M USD
-46.66 M USD
Jan 1, 2024
69.30 M USD
-32.70 M USD
-37.84 M USD
Jan 1, 2025
80.28 M USD
-33.36 M USD
-38.83 M USD
Jan 1, 2026 (e)
86.71 M USD
11.93 M USD
-28.62 M USD
Jan 1, 2027 (e)
95.73 M USD
13.17 M USD
-23.53 M USD
Jan 1, 2028 (e)
106.83 M USD
14.70 M USD
-17.03 M USD

TELA Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 4:41 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e
4.008.0015.0018.0029.0041.0058.0069.0080.0086.0095.00106.00
–100.0087.5020.0061.1141.3841.4618.9715.947.5010.4711.58
50.0025.0060.0061.1162.0765.8568.9766.6767.5067.5067.5067.50
2.002.009.0011.0018.0027.0040.0046.0054.0058.0564.1371.55
-16.00-19.00-18.00-25.00-29.00-40.00-41.00-32.00-33.0011.0013.0014.00
-400.00-237.50-120.00-138.89-100.00-97.56-70.69-46.38-41.2512.7913.6813.21
-21.00-21.00-22.00-28.00-33.00-44.00-46.00-37.00-38.00-28.00-23.00-17.00
––4.7627.2717.8633.334.55-19.572.70-26.32-17.86-26.09
51.686.496.1314.4314.5119.1624.4940.0751.6851.6851.6851.68
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales TELA Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue TELA Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare TELA Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares TELA Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against TELA Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

TELA Bio stock margins

The TELA Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TELA Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TELA Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
63.85 %
-100.73 %
-112.94 %
Jan 1, 2022
65.30 %
-97.17 %
-106.95 %
Jan 1, 2023
68.62 %
-71.19 %
-79.83 %
Jan 1, 2024
67.08 %
-47.18 %
-54.60 %
Jan 1, 2025
67.69 %
-41.55 %
-48.37 %
Jan 1, 2026 (e)
67.69 %
13.76 %
-33.01 %
Jan 1, 2027 (e)
67.69 %
13.76 %
-24.58 %
Jan 1, 2028 (e)
67.69 %
13.76 %
-15.94 %

TELA Bio Stock Revenue, EBIT, Earnings per Share

The TELA Bio earnings per share therefore indicates how much revenue TELA Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.03 USD
-2.05 USD
-2.29 USD
Jan 1, 2022
2.16 USD
-2.10 USD
-2.31 USD
Jan 1, 2023
2.39 USD
-1.70 USD
-1.91 USD
Jan 1, 2024
1.73 USD
-0.82 USD
-0.94 USD
Jan 1, 2025
1.55 USD
-0.65 USD
-0.75 USD
Jan 1, 2026 (e)
1.98 USD
0.23 USD
-0.65 USD
Jan 1, 2027 (e)
2.19 USD
0.25 USD
-0.54 USD
Jan 1, 2028 (e)
2.44 USD
0.28 USD
-0.39 USD

TELA Bio business model & stock analysis

TELA Bio Inc is an American medical technology company that specializes in the development and manufacture of innovative surgical implants. The history of this company began in 2012 when a group of experienced bioengineers and medical professionals decided to develop a better surgical tissue replacement material. The idea was to create a product that not only supports the healing process but is also safe, durable, and easy to handle. Over the years, TELA Bio has successfully implemented the business model of complete vertical integration, which means that the company takes care of everything from research and development to production, distribution, and marketing of its products. This allows the company to build closer relationships with its customers and improve the quality of its products by addressing the needs and requirements of its users. The core business of TELA Bio focuses on a wide range of surgical tissue replacement materials specifically designed for plastic and reconstructive surgery, hernia repair, and wound healing. These products are characterized by their high biocompatibility, strength, and flexibility, and provide a safe and effective solution for a variety of medical applications. Key products offered by TELA Bio include the OviTex® product family, which includes surgical mesh materials for supporting wound healing in hernia repairs and abdominal surgeries, as well as tissue replacement materials for breast reconstruction after mastectomy. These products are known for their high biocompatibility and ability to integrate into the surrounding tissue and restore natural tissue structures. In addition, TELA Bio also offers the TELADERM®-DH product, specifically developed for wound healing in diabetes patients. This product consists of a tissue replacement material that supports skin repair and reduces the risk of infection, particularly in patients with poorly healing wounds. Overall, TELA Bio has developed a wide range of products tailored to the needs of modern medicine. The company is focused on improving the quality of medical care and providing innovative solutions for surgical wound healing. With its successful implementations in research, production, and distribution, TELA Bio is well-positioned to continue growing and solidify its position as a leading provider of medical implants.

TELA Bio SWOT Analysis

Strengths

TELA Bio Inc is positioned as a leading medical technology company specializing in advanced surgical solutions. The company's core strengths include:

TELA Bio offers a range of innovative surgical products tailored to meet the needs of healthcare professionals. These products have been developed based on extensive research and clinical data, ensuring their efficacy and safety.

TELA Bio has successfully established its presence in the market and has a strong track record of delivering high-quality solutions to healthcare providers. This track record helps build credibility and trust among potential customers.

Weaknesses

TELA Bio Inc has identified the following weaknesses that warrant attention:

Despite its achievements, TELA Bio has a relatively limited market reach, primarily due to intense competition and challenges in penetrating new markets. Expanding its reach and market share may require significant investments and strategic partnerships.

As a medical technology company, TELA Bio is highly dependent on regulatory approvals to bring its products to market. Delays or rejections in obtaining regulatory clearance may hinder the company's growth and expansion plans.

Opportunities

TELA Bio Inc can leverage the following opportunities to drive its future success:

There is an increasing demand for innovative surgical solutions that provide improved patient outcomes and reduced healthcare costs. TELA Bio can capitalize on this trend by continuously developing and introducing advanced products that address unmet medical needs.

TELA Bio can explore opportunities to expand its market presence in untapped geographical regions. By strategically identifying target markets and establishing strong distribution networks, the company can increase its reach and revenue potential.

Threats

TELA Bio Inc must be cautious of the following threats that may impact its business:

The medical technology industry is highly competitive, with numerous players vying for market share. TELA Bio faces the threat of competitors introducing similar or superior products, potentially reducing its market position.

Regulatory frameworks governing the medical technology sector may undergo changes, posing challenges for TELA Bio's product development and commercialization efforts. It is crucial for the company to stay updated with evolving regulations and adapt accordingly.

TELA Bio Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

TELA Bio Employees
Details
Date
TELA Bio Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

TELA Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

TELA Bio historical P/E ratio, EBIT multiple, and P/S ratio

TELA Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

TELA Bio shares outstanding

The number of shares of TELA Bio was 51.68 M in 2025. This indicates how many shares TELA Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
14.51 M Stocks
Jan 1, 2022
19.16 M Stocks
Jan 1, 2023
24.49 M Stocks
Jan 1, 2024
40.07 M Stocks
Jan 1, 2025
51.68 M Stocks
Jan 1, 2026 (e)
51.68 M Stocks
Jan 1, 2027 (e)
51.68 M Stocks
Jan 1, 2028 (e)
51.68 M Stocks

Current TELA Bio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
4.08
Last Price
0.91
Currency
USD
12M Return Potential
348.80 %
LTM Return
0 %

TELA Bio Analyst Rating Actions

DateFirmActionRatingReliability
3/27/2026
Citizens
Citizens
MaintainedMarket Outperform–
3/25/2026
Piper Sandler
Piper Sandler
MaintainedNeutral51
3/25/2026
Lake Street
Lake Street
MaintainedBuy–
3/25/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
12/1/2025
Lake Street
Lake Street
MaintainedBuy–
11/18/2025
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
11/14/2025
Piper Sandler
Piper Sandler
MaintainedNeutral51
11/14/2025
Citizens
Citizens
MaintainedMarket Outperform–
3/21/2025
Piper Sandler
Piper Sandler
DowngradeOverweightNeutral51
3/21/2025
Citizens Capital Markets
Citizens Capital Markets
MaintainedMarket Outperform–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

TELA Bio Earnings Calls

2025

TELA Bio Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.18USD-20.41 MUSD-2026 Q2
5/12/2026-0.19USD-18.97 MUSD-2026 Q1
3/24/2026-0.19USD-21.47 MUSD-2025 Q4
11/13/2025-0.20USD-22.22 MUSD-2025 Q3
8/11/2025-0.18USD-21.09 MUSD-2025 Q2
11/7/2024-0.43USD-19.13 MUSD-2024 Q3
5/9/2024-0.43USD-16.52 MUSD-2024 Q1
3/19/2024-0.44USD-16.72 MUSD-2023 Q4
11/7/2023-0.52USD-15.55 MUSD-2023 Q3
8/8/2023-0.53USD-14.66 MUSD-2023 Q2

EESG©

Eulerpool ESG Scorecard© for the TELA Bio stock

43/100
28
Environment
53
Social
47
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

TELA Bio shareholder structure

% Name
17.62556%
EW Healthcare Partners
EW Healthcare Partners
11.67829%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
6.54628%
Lytton (Laurence W)
Lytton (Laurence W)
6.04869%
SilverArc Capital Management, LLC
SilverArc Capital Management, LLC
5.37362%
Stonepine Capital Management, LLC
Stonepine Capital Management, LLC
4.18220%
The Vanguard Group, Inc.
The Vanguard Group, Inc.

TELA Bio Beneficial Ownership Filings (SEC 13D/G)

Free Float
73.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
21.20%
OrbiMed Capital GP IV LLC
OrbiMed Capital GP IV LLC
SEC ↗
21.20%
OrbiMed Advisors LLC
OrbiMed Advisors LLC
SEC ↗
17.23%
EW Healthcare Partners Fund 2-UGP, LLC
EW Healthcare Partners Fund 2-UGP, LLC
SEC ↗
17.23%
EW Healthcare Partners Fund 2-GP, L.P.
EW Healthcare Partners Fund 2-GP, L.P.
SEC ↗
16.79%
R. Scott Barry
R. Scott Barry
SEC ↗
16.79%
Ronald Eastman
Ronald Eastman
SEC ↗
16.79%
Petri Vainio
Petri Vainio
SEC ↗
16.79%
Martin P. Sutter
Martin P. Sutter
SEC ↗
16.79%
2-UGP,
2-UGP,
SEC ↗
12.90%
Nantahala Capital Management, LLC
Nantahala Capital Management, LLC
SEC ↗

TELA Bio Executives and Management Board

11 members · avg. age 60 · 18 % women

AK

Mr. Antony Koblish (59)

Chief Executive Officer, Co-Founder, Director · since 2012

2.11 M USD

Management

RC

Mr. Roberto Cuca (57)

Chief Financial Officer, Chief Operating Officer

1.08 M USD
PT

Mr. Paul Talmo (58)

Chief Technology Officer

816,614.00 USD
JB

Mr. Jeffrey Blizard (56)

President · since 2024

88,395.00 USD
GF

Mr. Greg Firestone (66)

Chief Commercial Officer

–

Board of Directors

DE

Mr. Douglas Evans (60)

Independent Chairman of the Board

148,697.00 USD
FO

Ms. Federica O'Brien (67)

Independent Director

112,683.00 USD
VB

Mr. Vince Burgess (60)

Independent Director

107,683.00 USD
KA

Mr. Kurt Azarbarzin (62)

Independent Director

105,252.00 USD
WP

Mr. William Plovanic (56)

Independent Director

–
BR

Dr. Betty Jo Rocchio (57)

Independent Director

–

Frequently asked questions about TELA Bio

The business model of TELA Bio Inc focuses on developing and commercializing advanced surgical solutions for soft tissue reconstruction. By combining engineering innovation with proven biological constructs, TELA Bio aims to provide surgeons and patients with enhanced options for tissue repair and regeneration. TELA Bio's products, such as OviTex Reinforced BioScaffolds, offer a unique blend of biologic and synthetic materials to promote healing and improved patient outcomes. With a commitment to delivering high-quality, cost-effective solutions, TELA Bio strives to transform the landscape of soft tissue reconstruction and address unmet needs in various surgical specialties.

TELA Bio Inc is primarily active in the healthcare and medical device industry.

The main competitors of TELA Bio Inc in the market include companies such as Johnson & Johnson, Medtronic, Integra LifeSciences, and Baxter International. These companies also operate in the medical technology industry and offer products and solutions that are similar to TELA Bio Inc. Competing against these established players, TELA Bio Inc strives to differentiate itself through innovative product offerings, advanced technologies, and a focus on meeting the specific needs of patients and healthcare providers.

TELA Bio Inc is a company specializing in surgical reconstruction and healing technologies. Founded in 2012, TELA Bio has quickly made a name for itself in the medical industry. Inspired by the groundbreaking research of scientists and surgeons, TELA Bio develops innovative products aimed at improving patient outcomes in soft tissue reconstruction. With a strong focus on bioengineering and advanced materials, TELA Bio's solutions are designed to address various surgical challenges effectively. TELA Bio Inc's dedication to innovation and commitment to patients has positioned them as a leading player in the field, providing healthcare professionals with cutting-edge solutions for better patient care.

TELA Bio Inc has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) in February 2020, raising approximately $51 million. This marked a major achievement for TELA Bio Inc in terms of gaining access to public capital markets. Additionally, the company has received regulatory clearance for its OviTex portfolio of surgical implants, including OviTex PRS and OviTex RSM, which are used in various soft tissue reconstruction procedures. TELA Bio Inc has also experienced notable success in expanding its market presence and commercializing its products across the United States. These achievements demonstrate TELA Bio Inc's strong growth and determination in the medical technology field.

TELA Bio Inc is primarily present in the United States.

TELA Bio Inc represents a strong commitment to improving patient outcomes and quality of life through its innovative surgical reconstruction solutions. The company's corporate philosophy revolves around fostering partnerships with healthcare professionals and delivering unmatched value to both patients and providers. TELA Bio focuses on developing and commercializing advanced biomaterials and surgical implants, enabling surgeons to address complex soft tissue challenges effectively. With a dedication to research, development, and technological advancements, TELA Bio strives to create transformative medical solutions that support optimal patient healing and recovery.

Analysts currently set an average price target of 3.52 USD for the TELA Bio stock (median: 4.08 USD), implying +287.1 % versus the latest price. The consensus is based on 11 analyst ratings.

TELA Bio Analyst Price Targets 2026

11 analysts currently rate the TELA Bio stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect TELA Bio to generate revenue of 86.71 M USD and earnings per share of -0.55 USD.

TELA Bio Analyst Price Targets 2026

Converted at the current exchange rate, the TELA Bio share trades at 0.79 EUR (0.91 USD).

The TELA Bio share (TELA) is listed on 1 stock exchanges, including: NASDAQ (TELA).

The company TELA Bio Inc is a leading company in the field of biological tissue reconstruction and manufactures a wide range of innovative products. TELA Bio's business model is based on the development, manufacturing, and marketing of high-quality biotissue products used in the restoration and regeneration of tissues in the human body. TELA Bio's products include biological structures made from specially treated animal and/or plant skin. These structures are ideal for reconstructing damaged tissues such as muscle and fiber tissues and are used in various medical fields. The products are predominantly used in plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers its customers a variety of products tailored to their specific requirements and needs. These include biological mesh structures that can be used in abdominal wall reconstruction or breast tissue restoration, as well as long-term replacement structures for connective tissue, muscles, or tendons. Additionally, TELA Bio also provides custom-made products specifically tailored to the individual needs of the patient. Another important aspect of TELA Bio's business model is its collaboration with doctors, medical professionals, and scientists. The company continually invests in research and development to improve and enhance its products. Through close collaboration with medical professionals, TELA Bio ensures that its products meet the highest quality and safety standards. TELA Bio also follows a clear growth strategy by continuously expanding its customer base and expanding its product range. The company has expanded its presence in the global market and distributes its products in Europe, Asia, and South America. As TELA Bio operates in a growing market, there are numerous opportunities for future growth and further expansion. Overall, TELA Bio's business model is characterized by a high level of innovation, close collaboration with medical professionals, and a clear growth strategy. Through the development and manufacturing of high-quality biotissue products, the company makes an important contribution to improving medical care and enhancing the quality of life for patients worldwide. Answer: TELA Bio Inc is a leading company in the field of biological tissue reconstruction. They develop, manufacture, and market high-quality biotissue products used in the restoration and regeneration of human tissues. These products are used in various medical fields including plastic and reconstructive surgery, general surgery, gynecology, and thoracic surgery. TELA Bio offers a wide range of products tailored to the specific needs of their customers. They collaborate with doctors, medical professionals, and scientists to ensure the highest quality and safety standards. TELA Bio also follows a clear growth strategy and has expanded its presence in the global market. They contribute to improving medical care and enhancing the quality of life for patients worldwide.

The expected revenue of TELA Bio is 86.71 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of TELA Bio is -28.62 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of TELA Bio is currently -1.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the TELA Bio stock.

The price-to-sales ratio (P/S) of TELA Bio is currently 0.54. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the TELA Bio stock.

The Eulerpool Quality Score for TELA Bio is 3/10.

The ISIN of TELA Bio is US8723811084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of TELA Bio is A2PUP9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of TELA Bio is TELA. The ticker symbol is used to trade TELA Bio shares on the stock exchange.

TELA Bio paid dividends every year for the past 0 years.

TELA Bio is assigned to the 'Health' sector.

The dividends of TELA Bio are distributed in USD.

All fundamentals and in-depth analysis of TELA Bio

Our stock analysis for TELA Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TELA Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

TELA Bio Stock
TELA Bio Revenue→
TELA Bio Stock
TELA Bio Net Income→
TELA Bio Stock
TELA Bio P/E→
TELA Bio Stock
TELA Bio P/S→
TELA Bio Stock
TELA Bio EBIT→
TELA Bio Stock
TELA Bio Dividend→
TELA Bio Stock
TELA Bio Directors Dealings→
TELA Bio Stock
TELA Bio Stocks→
TELA Bio Stock
TELA Bio Market capitalization→
TELA Bio Stock
TELA Bio Debt→
TELA Bio Stock
TELA Bio Liabilities→
TELA Bio Stock
TELA Bio Equity→
TELA Bio Stock
TELA Bio AAQS→
TELA Bio Stock
TELA Bio Employees→
TELA Bio Stock
TELA Bio ROE→
TELA Bio Stock
TELA Bio ROA→
TELA Bio Stock
TELA Bio ROCE→
TELA Bio Stock
TELA Bio News→
TELA Bio Stock
TELA Bio Analyst Price Targets→

Health Stocks

Teladoc HealthTejnaksh HealthcareTeleflexTego ScienceTelix Pharmaceuticals LimitedTectonic TherapeuticTellgenTechno Medical PCLTelo GenomicsTechno Medica CoTelomir PharmaceuticalsTecan GroupAll Stocks A–Z →